1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Global Clinical Trials Review, H1, 2014

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Global Clinical Trials Review, H1, 2014" provides data on the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mucopolysaccharidosis II (MPS II) (Hunter Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis II (MPS II) (Hunter Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) to Metabolic Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Shire Plc 31
Clinical Trial Overview of Shire Plc 31
Green Cross Holdings Corporation 32
Clinical Trial Overview of Green Cross Holdings Corporation 32
Medical Resources International Pte Ltd 33
Clinical Trial Overview of Medical Resources International Pte Ltd 33
GlaxoSmithKline plc 34
Clinical Trial Overview of GlaxoSmithKline plc 34
Cytomedix, Inc. 35
Clinical Trial Overview of Cytomedix, Inc. 35
ArmaGen Technologies, Inc. 36
Clinical Trial Overview of ArmaGen Technologies, Inc. 36
Clinical Trial Overview of Top Institutes / Government 37
University of Minnesota 37
Clinical Trial Overview of University of Minnesota 37
Tokai University School of Medicine 38
Clinical Trial Overview of Tokai University School of Medicine 38
University of Rostock 39
Clinical Trial Overview of University of Rostock 39
Clinical and Translational Science Institute 40
Clinical Trial Overview of Clinical and Translational Science Institute 40
The University of Chicago 41
Clinical Trial Overview of The University of Chicago 41
Eunice Kennedy Shriver National Institute of Child Health and Human Development 42
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 42
Five Key Clinical Profiles 43
Appendix 84
Abbreviations 84
Definitions 84
Research Methodology 85
Secondary Research 85
About GlobalData 86
Contact Us 86
Disclaimer 86
Source 86

List of Tables
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Shire Plc, 2014* 31
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Green Cross Holdings Corporation, 2014* 32
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical Resources International Pte Ltd, 2014* 33
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 34
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytomedix, Inc., 2014* 35
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by ArmaGen Technologies, Inc., 2014* 36
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2014* 37
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Tokai University School of Medicine, 2014* 38
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Rostock, 2014* 39
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Clinical and Translational Science Institute, 2014* 40
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014* 41
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 42

List of Figures
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 85

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.